An Open Label Study Of Asciminib In Patients With Chronic Myeloid Leukemia In Chronic Phase
Seeking men and women 18 years of age and older who have chronic myeloid leukemia (CML) in chronic phase (CP) with and without the T315I mutation, to determine how well the treatment with asciminib works compared to previously used therapies.